Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Abemaciclib and Radiation Therapy for High-Risk Adipocytic Retroperitoneal Sarcomas
NCT06025747Phase 1Recruiting
- Sponsor
- University of Washington
- Start
- Mar 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abemaciclib in retroperitoneal sarcoma (RPS), Liposarcoma and dedifferentiated liposarcoma (DDL), sponsored by University of Washington. Primary endpoint: Recommended Phase 2 Dose at 28 days. Started Mar 2025; status: recruiting.
02
Drugs
abemaciclib
03
Conditions
retroperitoneal sarcoma (RPS)Liposarcomadedifferentiated liposarcoma (DDL)
Beyond the preview
Go deeper on NCT06025747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06025747.